{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:24:50Z","timestamp":1787246690796,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01808-9","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:14:13Z","timestamp":1780730053000},"page":"4155-4169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA"],"prefix":"10.1007","volume":"16","author":[{"given":"Justin","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha K.","family":"Kurosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Takiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan M.","family":"Sadrarhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griffith","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chien","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"1808_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14:81\u20139.","journal-title":"Autoimmun Rev"},{"key":"1808_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE Jr., Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.","journal-title":"Nat Rev Dis Primers"},{"key":"1808_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaad.2018.07.013","volume":"80","author":"S Lee","year":"2019","unstructured":"Lee S, Lee H, Lee CH, Lee WS. Comorbidities in alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80:466-77.e16.","journal-title":"J Am Acad Dermatol"},{"key":"1808_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjd.14497","volume":"175","author":"F Rencz","year":"2016","unstructured":"Rencz F, Gul\u00e1csi L, P\u00e9ntek M, Wikonk\u00e1l N, Baji P, Brodszky V. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol. 2016;175:561\u201371.","journal-title":"Br J Dermatol"},{"key":"1808_CR5","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","volume":"75","author":"LY Liu","year":"2016","unstructured":"Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol. 2016;75:806-12.e3.","journal-title":"J Am Acad Dermatol"},{"key":"1808_CR6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","volume":"11","author":"A Mostaghimi","year":"2021","unstructured":"Mostaghimi A, Napatalung L, Sikirica V, et al. Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review. Dermatol Ther (Heidelb). 2021;11:867\u201383.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1808_CR7","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20:S62\u20138.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1808_CR8","doi-asserted-by":"publisher","first-page":"967","DOI":"10.36849\/JDD.SF396143","volume":"22","author":"A Tosti","year":"2023","unstructured":"Tosti A. Alopecia areata: the clinician and patient voice. J Drugs Dermatol. 2023;22:967\u201375.","journal-title":"J Drugs Dermatol"},{"key":"1808_CR9","unstructured":"Olumiant (baricitinib). Prescribing information. Lilly USA; 2022. https:\/\/pi.lilly.com\/us\/olumiant-uspi.pdf. Accessed Jan 6, 2026."},{"key":"1808_CR10","unstructured":"Litfulo (ritlecitinib). Prescribing information. New York: Pfizer.; 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19638. Accessed Jan 6, 2026."},{"key":"1808_CR11","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase\u00a02b-3 trial. Lancet. 2023;401:1518\u201329.","journal-title":"Lancet"},{"key":"1808_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamadermatol.2013.3049","volume":"149","author":"KP Huang","year":"2013","unstructured":"Huang KP, Mullangi S, Guo Y, Qureshi AA. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol. 2013;149:789\u201394.","journal-title":"JAMA Dermatol"},{"key":"1808_CR13","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/1346-8138.16839","volume":"50","author":"P George","year":"2023","unstructured":"George P, Jagun O, Liu Q, et al. Prevalence of autoimmune and inflammatory diseases and mental health conditions among an alopecia areata cohort from a US administrative claims database. J Dermatol. 2023;50:1121\u20138.","journal-title":"J Dermatol"},{"key":"1808_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","volume":"151","author":"GC Mohan","year":"2015","unstructured":"Mohan GC, Silverberg JI. Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2015;151:522\u20138.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1808_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamadermatol.2022.6085","volume":"159","author":"S Lauron","year":"2023","unstructured":"Lauron S, Plasse C, Vaysset M, et al. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2023;159(3):281\u20138.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1808_CR16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1001\/jamadermatol.2024.2404","volume":"160","author":"A Mostaghimi","year":"2024","unstructured":"Mostaghimi A, Soliman AM, Li C, Barqawi YK, Grada A. Immune-mediated and psychiatric comorbidities among patients newly diagnosed with alopecia areata. JAMA Dermatol. 2024;160(9):945\u201352.","journal-title":"JAMA Dermatol"},{"key":"1808_CR17","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase\u00a03 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386:1687\u201399.","journal-title":"N Engl J Med"},{"key":"1808_CR18","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jamadermatol.2023.3109","volume":"159","author":"H Lee","year":"2023","unstructured":"Lee H, Huang KP, Mostaghimi A, Choudhry NK. Treatment patterns for alopecia areata in the US. JAMA Dermatol. 2023;159:1253\u20137.","journal-title":"JAMA Dermatol"},{"key":"1808_CR19","doi-asserted-by":"publisher","unstructured":"Gutierrez Y, Pourali SP, Jones ME, et al. Alopecia areata in the United States: a ten-year analysis of patient characteristics, comorbidities, and treatment patterns. Dermatol Online J. 2021;27(10). https:\/\/doi.org\/10.5070\/D3271055631.","DOI":"10.5070\/D3271055631"},{"key":"1808_CR20","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1007\/s12325-021-01845-0","volume":"38","author":"M Senna","year":"2021","unstructured":"Senna M, Ko J, Tosti A, et al. Alopecia areata treatment patterns, healthcare resource utilization, and comorbidities in the US population using insurance claims. Adv Ther. 2021;38:4646\u201358.","journal-title":"Adv Ther"},{"key":"1808_CR21","first-page":"1012","volume":"14","author":"ME Farhangian","year":"2015","unstructured":"Farhangian ME, McMichael AJ, Huang KE, Feldman SR. Treatment of alopecia areata in the United States: a retrospective cross-sectional study. J Drugs Dermatol. 2015;14:1012\u20134.","journal-title":"J Drugs Dermatol"},{"key":"1808_CR22","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1007\/s12325-022-02338-4","volume":"39","author":"M Fridman","year":"2022","unstructured":"Fridman M, Ray M, Gandhi K, Shy ME, Mostaghimi A. Treatment patterns and treatment satisfaction among adults with alopecia areata in the United States. Adv Ther. 2022;39:5504\u201313.","journal-title":"Adv Ther"},{"issue":"6","key":"1808_CR23","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/pde.15378","volume":"40","author":"M Hordinsky","year":"2023","unstructured":"Hordinsky M, Hebert AA, Gooderham M, et al. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase\u00a02b\/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. 2023;40(6):1003\u20139.","journal-title":"Pediatr Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01808-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01808-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01808-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:36Z","timestamp":1787243376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01808-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1808"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01808-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Justin Ko has served as a consultant and\/or investigator for Pfizer, Eli Lilly, Sanofi, and Abbvie. Genevieve Gauthier, Samantha K. Kurosky, Liza Takiya, Mojgan M. Sadrarhami, Griffith Bell, and Yi-Chien Lee are employees of and may hold stock or stock options in Pfizer. Benjamin Ungar is an employee of Mount Sinai and has received research funds (grants paid to the institution) from\u00a0Bristol Myers Squibb, Incyte, Rapt Therapeutics, Pfizer, and Sanofi. He is also a consultant for AbbVie, Arcutis Biotherapeutics, Apogee Therapeutics, Bristol Myers Squibb, Botanix Pharmaceuticals, Castle Biosciences, Ebla Holdco, Fresenius Kabi, Galderma, J&J, Leo Pharma, Lilly, Nektar Therapeutics, Pfizer, Primus Pharmaceuticals, Sanofi, Sun Pharma, UCB, Veradermics, and VRG Therapeutics.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) regulatory framework, Mirador Analytics Inc. has conducted a statistical disclosure risk analysis of Komodo\u2019s Komodo\u2009+\u2009OMNY dataset. This constitutes an Expert Determination as set out in 45 CFR \u00a7 164.514(b)(1). The Expert Determination confirmed that the dataset met the HIPAA Expert Determination de-identification standard. Accordingly, approval from an institutional review board was not required, and informed consent was not obtained.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}